Nanorobotics
Nanorobots for Targeting and Destroying Cancer Cells
Company Overview
Snapshot
Founded in May 2019 by Yossi Keret, Nanorobotics operates with 1–10 employees. The company is in the Pre-Funding stage and holds one patent. In November 2024, Nanorobotics ceased to operate.
Business overview
Nanorobotics is a preclinical-stage startup focused on cancer eradication through its patented light-activated nanomolecular platform technology. The company develops molecular therapies leveraging Molecular Nanomachines (MNMs) that mechanically drill through cell membranes, targeting cancers resistant to conventional treatments. Its leading molecule, MNM96, is designed for efficacy and safety, with plans to advance to human clinical trials. Nanorobotics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, Oncology, and Biotechnology.
Log in to access full profile ›Company Intelligence Q&A
- What is Nanorobotics' primary mission?
- Nanorobotics' primary mission is to eradicate cancer by utilizing its patented light-activated nanomolecular platform technology.
- What is the core technology developed by Nanorobotics?
- Nanorobotics develops molecular therapies based on Molecular Nanomachines (MNMs) that can mechanically drill through cell membranes, targeting cancers resistant to conventional treatments.
- Which product is Nanorobotics currently advancing?
- Nanorobotics is advancing its leading molecule, MNM96, which has shown promising preclinical efficacy and safety, towards human clinical trials.
- When was Nanorobotics founded?
- Nanorobotics was founded in May 2019.
- What is the current operational status of Nanorobotics?
- Nanorobotics ceased to operate in November 2024.